Selective killing of cancer cells by beta -lapachone: direct checkpoint activation as a strategy against cancer.
basic_science · Level V
Where this comes from
- Record sourced from PubMed, PMID 12598645.
- Also identified by PMC identifier 151399.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Most chemotherapeutic drugs kill cancer cells by indirectly activating checkpoint-mediated apoptosis after creating nonselective damage to DNA or microtubules, which accounts for their toxicity toward normal cells. We seek to target cancer cells by directly activating checkpoint regulators without creating such damage. Here, we show that beta-lapachone selectively induces apoptosis in cancer cells without causing the death of nontransformed cells in culture. This unusual selectivity against cancer cells is preceded by activation of S-phase checkpoint and selective induction of E2F1, a regulator of checkpoint-mediated apoptosis. This study suggests direct checkpoint activation as a strategy against cancer.
Medical subject headings
- Antibiotics, Antineoplastic
- Cell Cycle Proteins
- Cell Transformation, Neoplastic
- DNA-Binding Proteins
- Naphthoquinones
- Neoplasms